SCHEMBL30946225

SCHEMBL30946225

O=C(NCc1cc2cc(F)c(OCc3ccon3)cc2[nH]1)N1CCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.35
▸ DGAT2 Q96PD7 1/20 0.32
▸ RAB9A P51151 4/20 0.32
▸ NPC1 O15118 3/20 0.32
▸ ATM Q13315 1/20 0.32
▸ METTL3 Q86U44 2/20 0.32
▸ METTL14 Q9HCE5 2/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ PDGFRB P09619 1/20 0.31
▸ PDGFRA P16234 1/20 0.31
▸ KIT P10721 3/20 0.31
▸ GRM5 P41594 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ CASP1 P29466 1/20 0.30
▸ CASP7 P55210 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27247566 1.00 MAPK1 (0.35) MAPK1DGAT2RAB9ANPC1ATM
SCHEMBL30946285 0.98 MAPK1 (0.35) MAPK1DGAT2RAB9ANPC1ATM
SCHEMBL30946155 0.97 MAPK1 (0.35) MAPK1DGAT2RAB9ANPC1ATM
SCHEMBL27247576 0.97 MAPK1 (0.35) MAPK1DGAT2RAB9ANPC1ATM
SCHEMBL27247584 0.90 MAPK1 (0.35) MAPK1DGAT2RAB9ANPC1SMN1; SMN2
SCHEMBL30946076 0.90 MAPK1 (0.35) MAPK1DGAT2RAB9ANPC1SMN1; SMN2
SCHEMBL27247196 0.90 MAPK1 (0.37) MAPK1DGAT2RAB9ASMN1; SMN2PDGFRB
SCHEMBL27247267 0.89 CHRNA7 (0.34) MAPK1DGAT2RAB9ANPC1METTL3
SCHEMBL30920693 0.89 CHRNA7 (0.34) MAPK1DGAT2RAB9ANPC1METTL3
SCHEMBL27247097 0.89 ALK (0.35) MAPK1DGAT2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 MAPK1 3172/4885DGAT2 2906/4885RAB9A 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback